Scholarlink

Background <p>Human leukocyte antigen (HLA) class I encompasses peptide-binding proteins that regulate T-cell interactions. We examined HLA class I expression in prostate cancers (PC), exploring associations with clinical outcomes, molecular features, and tumor immune microenvironment.</p> Methods <p>We analyzed 8040 PC samples from the Caris Life Sciences database, stratifying them into HLA-high (upper quartile) and -low (lower quartile) groups. Genomic and transcriptomic alterations were compared. Immune cell fractions were inferred using quanTIseq, and overall survival (OS) data was obtained from insurance claims. Differences were computed with Cox proportional hazards.</p> Results <p>Among 66 cancer types, PC ranked 3<sup>rd</sup>-, 11<sup>th</sup>-, and 19<sup>th</sup>-lowest for HLA-A, -B, and -C expression, respectively. In PC, genes tied to androgen receptor (<i>AR</i>) signaling, immune checkpoint molecules (<i>CTLA4, PD-L1</i>), and the epithelial-mesenchymal transition were significantly higher in HLA-high tumors. HLA-high status was linked to greater tumor immune activity, marked by higher T cell fractions and enhanced immune hallmarks. HLA-high tumors were less likely to possess alterations in <i>AR, FOXA1</i>, and <i>CDK12</i>, but harbored increased alterations in tumor suppressor gene (<i>RB1</i>, <i>PTEN</i>) alterations. Tumors with high HLA-A and HLA-B had elevated TMB-H/MSI-H/dMMR status. Finally, shorter OS was observed in patients with high HLA-A or HLA-B expression, while longer OS was associated with high HLA-C expression.</p> Conclusions <p>In PC, elevated HLA class I levels correlate with immune activity, molecular characteristics, and clinical outcomes. We suggest considering HLA expression as a supplementary marker of immune activity in PC, alongside genetic mutations and transcriptomic markers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月25日

查看全文
  • Pornlada Likasitwatanakul,
  • Carissa Besonen,
  • Alexander K. Tsai,
  • Negar Sadeghipour,
  • Andrew Elliott,
  • Ali T. Arafa,
  • Rachel Passow,
  • Lisa Chesner,
  • Martin Felices,
  • Philippa R. Kennedy,
  • Akash Patnaik,
  • Vivek Narayan,
  • James Hamrick,
  • Laura A. Sena,
  • Nicholas A. Zorko,
  • Justin H. Hwang,
  • Emmanuel S. Antonarakis

摘要

Background

Human leukocyte antigen (HLA) class I encompasses peptide-binding proteins that regulate T-cell interactions. We examined HLA class I expression in prostate cancers (PC), exploring associations with clinical outcomes, molecular features, and tumor immune microenvironment.

Methods

We analyzed 8040 PC samples from the Caris Life Sciences database, stratifying them into HLA-high (upper quartile) and -low (lower quartile) groups. Genomic and transcriptomic alterations were compared. Immune cell fractions were inferred using quanTIseq, and overall survival (OS) data was obtained from insurance claims. Differences were computed with Cox proportional hazards.

Results

Among 66 cancer types, PC ranked 3rd-, 11th-, and 19th-lowest for HLA-A, -B, and -C expression, respectively. In PC, genes tied to androgen receptor (AR) signaling, immune checkpoint molecules (CTLA4, PD-L1), and the epithelial-mesenchymal transition were significantly higher in HLA-high tumors. HLA-high status was linked to greater tumor immune activity, marked by higher T cell fractions and enhanced immune hallmarks. HLA-high tumors were less likely to possess alterations in AR, FOXA1, and CDK12, but harbored increased alterations in tumor suppressor gene (RB1, PTEN) alterations. Tumors with high HLA-A and HLA-B had elevated TMB-H/MSI-H/dMMR status. Finally, shorter OS was observed in patients with high HLA-A or HLA-B expression, while longer OS was associated with high HLA-C expression.

Conclusions

In PC, elevated HLA class I levels correlate with immune activity, molecular characteristics, and clinical outcomes. We suggest considering HLA expression as a supplementary marker of immune activity in PC, alongside genetic mutations and transcriptomic markers.